Heron Therapeutics (HRTX)

$1.48 -0.01 (-0.67%)
Market Cap 273.21M
Revenue (ttm) 144.29M
Net Income (ttm) -13.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.41%
Debt to Equity Ratio 7.22
Volume 1,784,600
Avg Vol 2,149,992
Day's Range N/A - N/A
Shares Out 183.36M
Stochastic %K 76%
Beta 1.28
Analysts Strong Sell
Price Target $4.50

Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na...

Industry: Biotechnology
Sector: Healthcare
Phone: (858) 251-4400
Address:
100 Regency Forest Drive, Suite 300, Cary, United States
SpaghettiMonster
SpaghettiMonster Jan. 13 at 8:23 PM
$HRTX looking good
1 · Reply
BulICrunch
BulICrunch Jan. 13 at 4:08 PM
$HRTX load the dips bros, institutions will be loading the boat $2’s incoming soon
1 · Reply
BullMaven
BullMaven Jan. 13 at 3:46 PM
$HRTX 1.80+ will be filled. trend starting mid nov. is very bullish.
0 · Reply
Braddog
Braddog Jan. 13 at 2:35 PM
$HRTX And now do the shorts! Did you think this was going to go higher! 😡😡😡😡😡
0 · Reply
Smartynow
Smartynow Jan. 13 at 1:07 PM
$HRTX a bidding war will soon starts , usd 3.4 billion is not something to pass on by the big boys
0 · Reply
EMINENZ
EMINENZ Jan. 13 at 11:32 AM
$HRTX let's break 1.60$!! Come on
0 · Reply
Smartynow
Smartynow Jan. 13 at 2:01 AM
$HRTX
0 · Reply
CliffordCapital
CliffordCapital Jan. 12 at 10:15 PM
$HRTX let‘s break that EMA200 man come on!
0 · Reply
Braddog
Braddog Jan. 12 at 9:38 PM
$HRTX And the selloff
0 · Reply
BullMaven
BullMaven Jan. 12 at 7:37 PM
$HRTX
0 · Reply
Latest News on HRTX
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Jan 9, 2026, 9:29 AM EST - 4 days ago

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Dec 4, 2025, 8:15 AM EST - 5 weeks ago

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 3:26 PM EST - 2 months ago

Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

Nov 4, 2025, 8:00 AM EST - 2 months ago

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

Oct 29, 2025, 5:58 PM EDT - 2 months ago

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 21, 2025, 4:20 PM EDT - 3 months ago

Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value

Aug 15, 2025, 7:45 AM EDT - 5 months ago

Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value

Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:46 PM EDT - 5 months ago

Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript

Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress

Aug 8, 2025, 7:45 AM EDT - 5 months ago

Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress

Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

Aug 8, 2025, 7:45 AM EDT - 5 months ago

Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

HTGC

Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025

Aug 8, 2025, 6:00 AM EDT - 5 months ago

Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025

Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025

Jul 28, 2025, 9:42 PM EDT - 6 months ago

Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025

Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025

May 7, 2025, 3:38 PM EDT - 8 months ago

Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025

Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:38 AM EDT - 9 months ago

Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript

Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

May 6, 2025, 7:45 AM EDT - 9 months ago

Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

May 6, 2025, 7:30 AM EDT - 9 months ago

Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

Apr 28, 2025, 6:55 PM EDT - 9 months ago

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

Apr 22, 2025, 4:05 PM EDT - 9 months ago

Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 12:07 PM EST - 11 months ago

Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript

Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

Feb 27, 2025, 7:45 AM EST - 11 months ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025

Feb 13, 2025, 4:20 PM EST - 11 months ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

Dec 23, 2024, 4:05 PM EST - 1 year ago

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

Relief For Heron Therapeutics After The Court Win On Cinvanti

Dec 4, 2024, 3:01 PM EST - 1 year ago

Relief For Heron Therapeutics After The Court Win On Cinvanti

U.S. District Court Upholds Validity of CINVANTI® Patents

Dec 3, 2024, 4:36 PM EST - 1 year ago

U.S. District Court Upholds Validity of CINVANTI® Patents

Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 11:45 AM EST - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Nov 12, 2024, 7:55 AM EST - 1 year ago

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Nov 4, 2024, 5:00 PM EST - 1 year ago

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

Oct 29, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Oct 10, 2024, 4:08 PM EDT - 1 year ago

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Heron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 10:14 AM EDT - 1 year ago

Heron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call Transcript

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

Jul 30, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Jul 15, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

May 29, 2024, 8:05 AM EDT - 1 year ago

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript

May 7, 2024, 2:38 PM EDT - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

May 7, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 16, 2024, 4:24 PM EDT - 1 year ago

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

Apr 11, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 10:35 PM EDT - 2 years ago

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

Mar 12, 2024, 4:05 PM EDT - 2 years ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

Feb 28, 2024, 8:00 AM EST - 2 years ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

Heron Therapeutics Is Out Of Survival Mode

Feb 17, 2024, 1:54 AM EST - 2 years ago

Heron Therapeutics Is Out Of Survival Mode

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Jan 23, 2024, 8:00 PM EST - 2 years ago

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

Jan 7, 2024, 5:00 PM EST - 2 years ago

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

Heron Therapeutics Gets Back On Track

Dec 29, 2023, 3:14 PM EST - 2 years ago

Heron Therapeutics Gets Back On Track

SpaghettiMonster
SpaghettiMonster Jan. 13 at 8:23 PM
$HRTX looking good
1 · Reply
BulICrunch
BulICrunch Jan. 13 at 4:08 PM
$HRTX load the dips bros, institutions will be loading the boat $2’s incoming soon
1 · Reply
BullMaven
BullMaven Jan. 13 at 3:46 PM
$HRTX 1.80+ will be filled. trend starting mid nov. is very bullish.
0 · Reply
Braddog
Braddog Jan. 13 at 2:35 PM
$HRTX And now do the shorts! Did you think this was going to go higher! 😡😡😡😡😡
0 · Reply
Smartynow
Smartynow Jan. 13 at 1:07 PM
$HRTX a bidding war will soon starts , usd 3.4 billion is not something to pass on by the big boys
0 · Reply
EMINENZ
EMINENZ Jan. 13 at 11:32 AM
$HRTX let's break 1.60$!! Come on
0 · Reply
Smartynow
Smartynow Jan. 13 at 2:01 AM
$HRTX
0 · Reply
CliffordCapital
CliffordCapital Jan. 12 at 10:15 PM
$HRTX let‘s break that EMA200 man come on!
0 · Reply
Braddog
Braddog Jan. 12 at 9:38 PM
$HRTX And the selloff
0 · Reply
BullMaven
BullMaven Jan. 12 at 7:37 PM
$HRTX
0 · Reply
slayer2408
slayer2408 Jan. 12 at 6:58 PM
$HRTX does anyone know how many watchers we had before the news release on Friday?
1 · Reply
jacksonjohn750
jacksonjohn750 Jan. 12 at 6:56 PM
$HRTX Is that order still open?
1 · Reply
Judykay
Judykay Jan. 12 at 6:40 PM
$HRTX Well Well
1 · Reply
keypatience
keypatience Jan. 12 at 6:35 PM
$HRTX
0 · Reply
slayer2408
slayer2408 Jan. 12 at 5:42 PM
$HRTX This movement is very similar to the price action we had from .50 to $4.
1 · Reply
BullMaven
BullMaven Jan. 12 at 4:28 PM
$HRTX 1.80+ next step
0 · Reply
jacksonjohn750
jacksonjohn750 Jan. 12 at 3:57 PM
$HRTX He will buy again today and sell it again tomorrow for 1.3s and repeat
2 · Reply
Prospero33
Prospero33 Jan. 12 at 3:48 PM
$HRTX https://x.com/annvandersteel/status/2010727387663827031?s=12&t=DUyf4HucfCqh8wa2FdmcGA
0 · Reply
CliffordCapital
CliffordCapital Jan. 12 at 3:39 PM
$KPTI one thing I find particularly disturbing is that every company so far like $DAWN $HRTX comes out early with Q4 projections because they are so good!! Why would you report bad/missed numbers before the actual earnings date? Huh??
2 · Reply
Braddog
Braddog Jan. 12 at 3:20 PM
$HRTX This will not go above $1.5 unless heron gets a big investor to buy a lot or maybe by the end of the year we get some great sales growth numbers Because the shorts own this
3 · Reply
BulICrunch
BulICrunch Jan. 12 at 2:46 PM
$HRTX the portal has opened
0 · Reply
Braddog
Braddog Jan. 12 at 2:34 PM
$HRTX Wouldn’t surprise me if we see $1.3 again. Or lower
5 · Reply